Treatment of medication-related osteonecrosis of the jaw with cell therapy.
AuteursBouland CL, Javadian R, Gilis S, Yanni A, Le Clercq M, Mestrallet P, Kampouridis S, Bron D, Lalmand M, Vanden Eynden X, Boutremans E, Dequanter D, Loeb I, Philippart P, Lagneaux L, Meuleman N
Treatment of medication-related osteonecrosis of the jaw with cell therapy.
AuteursBouland CL, Javadian R, Gilis S, Yanni A, Le Clercq M, Mestrallet P, Kampouridis S, Bron D, Lalmand M, Vanden Eynden X, Boutremans E, Dequanter D, Loeb I, Philippart P, Lagneaux L, Meuleman N
Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.
AuteursPradeep C-, Zeisel A, Köstler WJ, Lauriola M, Jacob-Hirsch J, Haibe-Kains B, Amariglio N, Ben-Chetrit N, Emde A, Solomonov I, Neufeld G, Piccart M, Sagi I, Sotiriou C, Rechavi G, Domany E, Desmedt C, Yarden Y
Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.
AuteursPradeep C-, Zeisel A, Köstler WJ, Lauriola M, Jacob-Hirsch J, Haibe-Kains B, Amariglio N, Ben-Chetrit N, Emde A, Solomonov I, Neufeld G, Piccart M, Sagi I, Sotiriou C, Rechavi G, Domany E, Desmedt C, Yarden Y
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.
AuteursBardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Kalinsky K, Cortés J, Shaughnessy JO, Diéras V, Carey LA, Gianni L, Piccart-Gebhart M, Loibl S, Yoon OK, Pan Y, Hofsess S, Phan SC, Hurvitz SA
